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Breast cancer is the most common cancer among women where it is associated with
considerable morbidity and mortality. The aim of this study was to investigate the asso-
ciation between insulin, estradiol levels and body mass index (BMI) as risk factors for
breast cancer. Methods: 80 women newly diagnosed with breast cancer stage IeIII invasive
breast cancer, were selected randomly and divided in two groups: 40 pre-menopausal aged
26e46 years and 40 post-menopausal aged 52e90 years. Radioimmunoassay used for
serum insulin levels measurement, ELISA was used for estradiol levels and BMI calculated
by weight (kg)/height (m2). Results: Insulin levels in premenopausal (16.6 ± 10.5) and
postmenopausal (17.9 ± 8.8); breast cancer patients showed increasing pattern from the
normal levels (4.0e16.0 mIU/ml). While, the levels of estradiol in premenopausal (233 ± 173)
and postmenopausal, (549 ± 468); estradiol level in postmenopausal was higher than
normal level (50e300 ng/ml), its level showed significantly increase in postmenopausal
breast cancer (P.Value ¼ 0.001). Conclusion: Insulin levels increased in pre- and post-
menopausal breast cancer patients while estradiol levels do not showed association with
premenopausal breast cancer. High BMI, high insulin and estradiol levels in post-
menopausal women may be considered as risk factors for breast cancer.
Copyright © 2015, The Egyptian Society of Radiation Sciences and Applications. Production
and hosting by Elsevier B.V. This is an open access article under the CC BY-NC-ND license
(http://creativecommons.org/licenses/by-nc-nd/4.0/).1. Introduction
Breast cancer is one of the most common types of cancer that
affects millions of women around the world (Parkin, Ferlay, &gy Commission, Khartoum
m (A.S. Mahmoud).
gyptian Society of Radiat
iety of Radiation Sciences
icense (http://creativecomPisani, 2005). Insulin level is one of the established risk factors
for breast cancer (Muti et al., 2002); it may be associated with
common risk factors such as high body mass index (BMI).
Insulin is an important metabolic hormone that affects body
fat mass (Gisela, 2005). Estradiol is important in sexual, Sudan.
ion Sciences and Applications.
andApplications. Production and hosting by Elsevier B.V. This is an
mons.org/licenses/by-nc-nd/4.0/).
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in the ovaries in premenopausal women, and mainly in fat
tissue in postmenopausal women. Estradiol in the blood is
linked to an increased risk of breast cancer in women after
menopause (Key et al., 2011). Hormone balance that may
promote breast cancer growth include elevated levels of
circulating or tissue estrogens and insulin which have been a
key role in the development and progression of breast cancer
(Pollak, 2008); some studies in Western countries have found
associations between higher BMI and a higher risk of death
among women with breast cancer (Masaaki et al., 2012),
although other studies have found no such association
(Barnett et al., 2008).Fig. 1 e Insulin and estradiol levels among study
population.2. Materials and methods
A cross sectional study of 80 Sudanese women newly diag-
nosed with breast cancer, they were not used any medication
including hormone replacement therapy, they were randomly
selected to participate in the study. Serum insulin level was
measured by using radioimmunoassay (RIA) with polyclonal
antibody and antigen I125labeled (Beijin Isotope Nuclear Elec-
tronic Machine Co. LTD, China). The normal range of insulin
level is from 4.0 to 16.0 mIU/ml while estradiol levels were
measured by ELISA kits with normal range (50e300 ng/ml) and
BMI was calculated using the following equation [weight (kg)/
height (m2)]. The patients were classified as underweight 18.5,
normal weight in ranged 18.5e24, over weight in ranged
25e29.9 and obese 30 (kg/m2).
2.1. Statistical analysis
Data analyzed by using the computer program SPSS version
20.0 for frequencies, percentage, mean and standard devia-
tion. Linear correlations were performed by using the Pear-
son's Correlation Coefficient, r. p  0.05 was considered
significant.Table 1 e Themean levels of Insulin and Estradiol among
BMI groups in premenopausal women with breast
cancer.
BMI (kg/m2) Number (%) Mean ± SD
Estradiol
(50e300 ng/ml)
Insulin
(4e16.0 mIU/ml)
Normal weight 16 (40%) 265.1 ± 243.1 17.4 ± 12.1
Over weight 14 (35%) 195.5 ± 151.1 18.5 ± 9.3
Low weight 8 (20%) 244.9 ± 142.1 10.2 ± 1.9
Obese 2 (5%) 192 ± 45 23.1 ± 213. Results
Themean levels and standard deviation of insulin in both pre-
and post-menopausal breast cancer patients showed
increasing pattern from the normal levels premenopausal
(16.6 ± 10.5) and postmenopausal (17.9 ± 8.8), and therewas no
significant difference (P.Value ¼ 0.5), which may indicate that
there is a relationship between high insulin and breast cancer.
While, the levels of estradiol in premenopausal (233 ± 173) and
postmenopausal (549 ± 468), estradiol in postmenopausal was
higher than normal levels (50e300 ng/ml), it's significantly
increased in postmenopausal breast cancer (P.Value ¼ 0.001)
as shown in Fig. 1. Regarding insulin serum levels there was
no significant correlation with BMI in pre- and post-
menopausal breast cancer patients (r ¼ 0.0, P ¼ 0.9 and
r ¼ 0.1, P ¼ 0.4 respectively), also estradiol serum levels and
BMI had no significant correlation (r¼ 0.01, P¼ 0.9 and r¼ 0.05,
P ¼ 0.7 respectively). However, insulin level in pre-
menopausal women increased in normal weight, over
weight and obese; underweight women had normal insulinlevels, while estradiol levels based in the normal levels as
shown in Table 1. Among postmenopausal, the mean levels of
insulin were increased in normal weight and obese; while
estradiol levels were increased in different BMI groups as
shown in Table 2.4. Discussion
This study demonstrated that BMI associated with insulin and
estradiol levels at diagnosis. Our findings showed high insulin
level in both pre- and post-menopausal women with breast
cancer. In a relevant study, positive association was found
between insulin level and breast cancer in both pre- and post-
menopausal women (Nichols et al., 2009). Insulin has been
shown to stimulate cell proliferation in normal breast tissue
and in human breast cancer cells (Lawlor, Smith, & Ebrahim,
2004). In contrast another study showed that insulin level
was strongly correlated with BMI in non-diabetic women
newly diagnosed breast cancer (Chappell et al., 2001); the
Table 2 e Themean levels of Insulin and Estradiol among
BMI groups in postmenopausal women with breast
cancer.
BMI (kg/m2) Number (%) Mean ± SD
Estradiol
(50e300 ng/ml)
Insulin
(4e16.0 mIU/ml)
Normal weight 8 (45%) 495 ± 411 18.4 ± 8.0
Over weight 8 (20%) 808 ± 730 15.3 ± 8.7
Low weight 5 (12.5%) 596 ± 457 14.3 ± 5.9
Obese 9 (22.5%) 401 ± 193.9 21.3 ± 11.5
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non-diabetic women who had normal weight (Goodwin et al.,
2002), which confirms our finding that insulin level increased
in women who had normal weight in both pre- and post-
menopausal women with breast cancer. Also meta-analysis
study showed non-significant correlation between BMI and
breast cancer risk during pre-menopausal, but a significant
correlation during post-menopausal period (Pamela et al.,
2002). However, among pre-menopausal women, insulin
level was increased in women who had a normal weight only,
finding a possible link between insulin levels and breast can-
cer risk is less clear in pre-menopausal women (Cheraghi,
Poorolajal, Hashem, Esmailnasab, & DoostiIrani, 2012); but
several studies suggested that high body mass index is asso-
ciated with a reduced risk in pre-menopausal women
(Eliassen, Tworoger, Mantzoros, Pollak, & Hankinson, 2007),
also pre-menopausal women who are overweight or obese
have a lower risk of breast cancer. Explain this relation not
well understood (Norman et al., 2006); however, serum
estradiol levels do not show a significant association with
premenopausal breast cancer risk (Kaaks et al., 2014) which
confirms our finding, while seven studies found that higher
blood estrogen levels increased breast cancer risk in pre-
menopausal women (Teras et al., 2011), An inverse association
between BMI and risk of premenopausal breast cancer has
been observed in a number of epidemiologic studies;
Furthermore, premenopausal women with a high BMI have
lower estradiol levels even when accounting for an ovulation
(Tworoger et al., 2006). Among post-menopausal group, the
insulin level was increased in normal weight and obese
women, while underweight and overweight women had
normal insulin level. Our findings are similar to this study
showing that obesity is associated with high levels of insulin;
hyperinsulinemia is an independent risk factor for breast
cancer and may have a role in explaining the obesity-breast
cancer relationship; Strong positive association between the
risk of breast cancer and insulin levels in postmenopausal
women was found (Yang et al., 2011). The poor association of
obesity and breast cancer outcomes may be mediated by in-
sulin (Gunter et al., 2009), also another study found a positive
association between hyperinsulinemia and post-menopausal
breast cancer only among women who had a BMI greater
than 25 kg/m (Goodwin et al., 2008). Losing weight after
menopause may help lower risk of breast cancer (Muti et al.,
2002). Several studies considered high BMI and post-
menopausal breast cancer patients is directly related to
circulating estrogen levels (Lukanova et al., 2004); insulin mayalso play a role in breast carcinogenesis via the effects of in-
sulin, insulin like growth factor (IGF) and the estrogen
signaling pathways in breast tissue (Key et al., 2011), also
hyperinsulinemia induces proliferative tissue abnormalities
because of the strong anabolic effect of insulin, which results
in stimulated DNA synthesis and cell proliferation (Mawson
et al., 2005). The present results suggests that insulin level
influence breast cancer risk through direct effects on breast
cell proliferation, then metabolites affect; and post-
menopausal-obesity relationship may be mediated by insu-
lin and estrogen levels; normal weight and obesity are asso-
ciated with high insulin and estradiol levels among post-
menopausal breast cancer patients at diagnosis. Also
normal-weight women with high insulin or estradiol levels in
cancer patients were at approximately the same risk of breast
cancer as obese women with high insulin or estradiol serum
levels.5. Conclusion
Insulin levels increased in pre- and post-menopausal women
with breast cancer; while estradiol levels, did not show any
associationwith premenopausal breast cancer. High BMI, high
insulin and estradiol levels in post-menopausal women may
be considered as risk factors for breast cancer; and weight
gain must be avoided.
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